Overcoming Drug Resistance in Gynecologic Cancers

1st Edition, Volume 17 - August 11, 2021
Imprint: Academic Press
Editors: Riyaz Basha, Sarfraz Ahmad
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 4 2 9 9 - 5
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 4 3 0 0 - 8

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics,… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers.

Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

Cover image
Title page
Table of Contents
Copyright
Cover Image Insert
Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
About the Series Editor
Aims and Scope of the Volume
About the Volume Editors
Preface
Contributors
Chapter 1: Introduction to gynecologic cancers: Emphasis on pathogenesis, incidence, and diagnosis
Abstract
Introduction
Uterine cancer
Ovarian cancer
Cervical cancer
Vulvar cancer
Vaginal cancer
Conclusions
Chapter 2: Lifestyle, nutrition, and risk of gynecologic cancers
Abstract
Introduction
Nutrition
Risk factors
Lifestyle
Conclusions and prospects
Chapter 3: Drug resistance in gynecologic cancers: Findings and underlying mechanisms
Abstract
Introduction
Drug resistance in endometrial (uterine) cancer
Drug resistance in ovarian cancer
Drug resistance in cervical cancer
Conclusions and future perspectives
Chapter 4: Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers
Abstract
Introduction
Key biological mechanisms of drug resistance
Targeted therapies to combat multidrug resistance
Concluding remarks and future perspectives
Chapter 5: Current treatment modalities in major gynecologic cancers: Emphasis on response rates
Abstract
Introduction
Cervical cancer
Ovarian cancer
Endometrial cancer
Conclusions and future perspectives
Chapter 6: Drug resistance in gynecologic cancers: Emphasis on noncoding RNAs and drug efflux mechanisms
Abstract
Introduction
Cervical cancer
Drug resistance mechanisms in cervical cancer
Ovarian cancer
Drug resistance mechanisms in ovarian cancer
Endometrial cancer
Drug resistance mechanisms in endometrial cancer
Conclusions
Chapter 7: Genetic polymorphisms in gynecologic cancers
Abstract
Introduction
Types of gynecologic cancers
Conclusion
Chapter 8: Overcoming drug resistance in cervical cancer: Chemosensitizing agents and targeted therapies
Abstract
Introduction/Background
Pathophysiology of cervical cancer
Cervical cancer treatment options
Resistance to chemotherapeutic agents and ways to overcome resistance
Conclusions and future perspectives
Chapter 9: Immune response, inflammation pathway gene polymorphisms, and the risk of cervical cancer
Abstract
Introduction
Single-nucleotide polymorphisms in susceptibility to cervical tumors
Immune regulator gene
Interleukin-1B gene
Interleukin-10 gene
Interleukin-12 gene
Interferons-γ gene
Tumor necrosis factor a gene
Human leukocyte antigen genes
Glutathione-S-transferase gene polymorphisms
p53 codon polymorphism
Murine double minute 2SNPs
Fas gene promoter polymorphism
Conclusions and future perspectives
Chapter 10: Overcoming chemotherapy resistance in endometrial cancer
Abstract
Introduction
Wnt/β-catenin signaling pathway
PI3K-AKT-mTOR signaling pathway
EGFR/FGF-Ras-Raf-MEK-ERK signaling pathway
HIF-1 signaling pathway
Conclusions and future perspectives
Chapter 11: Chemoresistance in uterine cancer: Mechanisms of resistance and current therapies
Abstract
Endometrial cancer
Current treatments of endometrial cancer
Mechanisms of chemoresistance in endometrial cancer
Overcoming chemoresistance-targeted therapies
Additional concepts, targets, and mechanisms
Chapter 12: Ovarian cancer: Targeted therapies and mechanisms of resistance
Abstract
Introduction
Targeting efflux pumps
Targeting repair mechanisms
Targeting PI3K/AKT pathway
Targeting mToR
Targeting epithelial growth factor receptors
Targeting the estrogen-signaling pathways
Targeting p53
Conclusions and future perspectives
Chapter 13: Overcoming drug resistance in ovarian cancer: Chemo-sensitizing agents, targeted therapies
Abstract
Introduction
Mechanisms of resistance of ovarian cancer cells to drugs
Mutations
Altered signaling pathways
Tumor hypoxia
Oxidative stress
Resistance of cancer stem cells
Transcription factors
Epithelial mesenchymal transition
Tumor microenvironment
Conclusions
Highlights
Chapter 14: Resistance to chemotherapy among ethnic and racial groups: Health disparities perspective in gynecologic cancers
Abstract
Introduction
Conclusions and future perspectives
Chapter 15: Future perspectives and new directions in chemosensitizing activities to reverse drug resistance in gynecologic cancers: Emphasis on challenges and opportunities
Abstract
Introduction
Current challenges in chemosensitization research for gynecologic cancers
Future development in chemosensitization research for gynecologic cancers
Conclusions
Index

Riyaz Basha

Doctor Riyaz Basha is an Associate Professor & Vice Chair for Research in the Department of Pediatrics and Women’s Health, Texas College of Osteopathic Medicine, The University of North Texas Health Science Center (UNTHSC) at Fort Worth, TX, USA. He graduated with a PhD degree in 1999 from the Sri Venkateswara University, Tirupati, India, and received postdoctoral training at the University of Rhode Island, RI, USA. Before joining the UNTHSC in 2013, Dr. Basha was appointed as an Assistant Professor at the Cancer Research Institute of the MD Anderson Cancer Center at Orlando (currently named as UF Cancer Center), Orlando, FL, USA. Dr. Basha’s research is focused on improving cancer therapies in children, adolescents and adults. He has been working closely with physicians and researchers with emphasis on the translational principle of “bench to bedside”. He has been investigating on drug resistance and novel strategies to improve the response of standard care/treatment, especially chemotherapy for various cancers including ovarian cancer. He has published his research findings in high impact factor journals such as Journal of Biological Chemistry, Cancer Letters, Cancer Medicine, Critical Reviews in Oncology/Hematology, and Gynecologic Oncology. Dr. Basha is a member of several scientific societies, including the Association of Biotechnology and Pharmacy (ABAP), American Association for Cancer Research, American Society of Clinical Oncology, and American Association for Clinical Chemistry (AACC) Academy. He became Fellow of the ABAP and the AACC Academies, respectively, in 2014 and 2019. He is the recipient of numerous competitive grants from the National Institutes of Health, Hyundai Hope On Wheels, non-profit foundations, and awards including the Young Scientist Travel Award from the Asian Pacific Society for Neurochemistry, four research presentation awards from the Society of Toxicology (USA), and the best presentation award at the International Conference on Drug Discovery and Therapy held in Dubai, UAE. Dr. Basha co-authored more than 100 peer-reviewed publications, served as Guest Editor for two journals, and serving as peer reviewer for more than 50 scientific journals. His research works are extensively cited by the peers globally.

Affiliations and expertise

Associate Professor, Department of Pediatrics and Women’s Health, University of North Texas Health Science Center (UNTHSC), USA

Sarfraz Ahmad

Prof. Sarfraz Ahmad is Director of Clinical Research at Gynecologic Oncology Program of AdventHealth Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD in Biochemistry from North-Eastern Hill University, Shillong. Prof. Ahmad’s research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology, hematology, and gastroenterology patients and to better understand the cellular/molecular mechanisms of cancer and related thromboembolic/hematologic disorders. Prof. Ahmad has published over 275 peer-reviewed scholarly research articles and book chapters, and over 400 scientific abstracts. He is a reviewer and has editorial responsibilities for several biomedical journals and books; and has received competitive research grants and national/international awards for his research contributions/accomplishments

Affiliations and expertise

AdventHealth Cancer Institute, Orlando, FL, United States

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health